Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Common Questions From Patients About Adalimumab Biosimilars

May 10th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

The Top 5 Biosimilar Articles for the Week of May 6

May 10th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 6, 2024.

Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability

May 9th 2024

By Skylar Jeremias

Article

As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.

Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market

May 8th 2024

By Skylar Jeremias

Article

Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.

Part 1: Unlocking the Potential of Biosimilars to Improve Health Equity

May 7th 2024

By Cameron Santoro

Article

Biosimilars offer a promising path to affordable, effective treatment, but barriers remain for underserved communities. This 2-part series explores the potential of biosimilars to improve health equity while addressing the obstacles that currently prevent access.

Quiz: The US Biosimilar Regulatory System

May 7th 2024

By The Center for Biosimilars Staff

Article

Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, postmarket safety, and more. Ready for the challenge?

BioRationality—FDA’s Guidance on Promotional Labeling

May 6th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, explains FDA's new guidance on promotional labeling as well as challenges and insights into how this new guidance will impact biosimilars.

Biosimilars Policy Roundup for April 2024—Podcast Edition

May 5th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.

Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment

May 4th 2024

By Deana Ferreri, PhD

Article

A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.

Copay Assistance Programs for Adalimumab Biosimilars

May 3rd 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.